DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Tatva Chintan Pharma Chem Limited — Analysts/Institutional Investor Meet/Con. Call Updates

NSE 1 hr ago·13 Oct 2026, 7:08 am

Tatva Chintan Pharma Chem

Tatva Chintan Pharma Chem has announced the schedule for its upcoming analyst and institutional investor meeting. The company has informed the stock exchange about the specific dates for this event, which is a standard practice for publicly traded firms to communicate with market participants.

This meeting is significant for investors as it provides an opportunity for the management to discuss the company's current performance and future outlook. Retail investors often watch these calls to gauge management sentiment and gather insights into the company's strategic direction.

Investors should pay close attention to the commentary regarding the company's order book, operational efficiency, and any guidance provided for the upcoming quarters. This information can help in assessing the stock's potential for the near term.